Merck's hepatitis C drug boceprevir gains FDA panel's support

04/27/2011 | Wall Street Journal, The

An FDA panel of outside experts unanimously endorsed the approval of Merck & Co.'s boceprevir, saying the drug candidate marks an advance in the treatment of hepatitis C. The panel affirmed clinical data showing the efficacy of boceprevir in combination with standard medicines ribavirin and pegylated interferon. Merck proposed to commercialize it as Victrelis.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ